Adamas Pharmaceuticals, Inc. Loss Form

See If You Qualify For Monetary Reward

Levi & Korsinsky, LLP does not share your information with others. There is no cost or obligation for you to submit.

Submit Transaction Detail Now (Optional)

- OR -

    This submission does not create an attorney-client relationship. If we believe that you might be an appropriate lead plaintiff, we will contact you to discuss whether to establish an attorney-client relationship.

    FAX: 212-363-7171

    According to a recently filed complaint, before launching Gocovri, a medicine for treating dyskinesia in Parkinson's disease patients treated with levodopa therapy, Adamas knew it faced significant roadblocks that would dramatically reduce its ability to sell the drug, yet did not inform—and actively misled—the market about this problem. Adamas failed to disclose known risks and trends that impacted the company before, during, and after the Company’s Second Public Offering in January 2018 (“SPO”). Therefore, when Adamas held its SPO in January 2018, it was able to offer its stock at $41.50 per share for gross proceeds of $134 million. In October 2018, Merrill Lynch released a study that cast doubt on Gocovri’s ability to achieve a sizeable market share, and highlighted a number of factors that made clear how Adamas omitted critical information. In March 2019, Adamas walked-back prior growth estimates and refused to make further predictions about Gocovri’s ability to achieve a sizeable market share. On this news, Adamas’s stock fell 33% to $8.16 per share, a decline of over 80% in the approximate year following the SPO.